UAE To Trial Sinopharm in Children From 3 to 12

  • Publish date: Thursday، 10 June 2021
UAE To Trial Sinopharm in Children From 3 to 12
Related articles
Students Aged 16 and Above Need Vaccination To Return To Classes
UAE Approves Use of Sinopharm Vaccine for 3-17 Years Children
900 Children Join UAE's Sinopharm Vaccine Study

Under the supervision of the Ministry of Health and Prevention (MOHAP), the UAE has begun to trial the Sinopharm COVID-19 vaccine in children aged 3 to 17 to study the impact on their immune system.

The study has been approved by the Department of Health – Abu Dhabi. The capital media office said that the study will monitor the immune response to the vaccine in 900 children of different nationalities.

Dr Nawal Al Kaabi, Chairwoman of the National COVID-19 Clinical Management Committee, who is leading the study, explained that the Sinopharm immune bridge study has been designed to ensure "children are able to receive the vaccine safely".

Each child will participate with the full consent of their parents and will be closely monitored at every step of the process.

The authorities added that it's a significant step in combating the pandemic and will support the planning process for the safe return to schools.

The study’s preliminary results will be announced "once available".  

Image Credit: Unsplash